Gossamer Bio is a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies in immunology, inflammation, and oncology. Its lead product candidate, seralutinib, targets pulmonary arterial hypertension, positioning the company at the forefront of the biopharma landscape with a commitment to addressing significant unmet medical needs.
